EPITHELIOID SARCOMA
Clinical trials for EPITHELIOID SARCOMA explained in plain language.
Never miss a new study
Get alerted when new EPITHELIOID SARCOMA trials appear
Sign up with your email to follow new studies for EPITHELIOID SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus + drug combo targets Tough-to-Treat sarcomas
Disease control OngoingThis study is testing whether combining two immunotherapy drugs can help control advanced sarcoma, a rare and aggressive cancer. The trial is for adults with certain types of sarcoma that have spread or cannot be surgically removed, and who have typically tried at least one other…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for tough sarcomas: adding a targeted drug to standard treatment
Disease control OngoingThis study is for patients with newly diagnosed, high-risk soft tissue sarcomas that can be removed by surgery. It tests whether adding a drug called pazopanib to standard pre-surgery treatments (radiation with or without chemotherapy) helps shrink tumors more effectively and imp…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for kids with Ultra-Rare, aggressive cancers
Disease control OngoingThis study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New immune attack on rare, aggressive cancers
Disease control OngoingThis study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…
Matched conditions: EPITHELIOID SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC